refs[] |
{'index': 0, 'target_release_id': None, 'extra': {'authors': ['B Björkstrand'], 'doi': '10.1182/blood.v88.12.4711.bloodjournal88124711', 'unstructured': 'Björkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J et al (1996) Allogeneic stem cell transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88:4711–4718. https://doi.org/10.1182/blood.V88.12.4711.bloodjournal88124711', 'volume': '88'}, 'key': '4514_CR1', 'year': 1996, 'container_name': 'Blood', 'title': None, 'locator': '4711'}
{'index': 1, 'target_release_id': None, 'extra': {'authors': ['F Garban'], 'doi': '10.1182/blood-2005-09-3869', 'unstructured': 'Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, dePrijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P, for the Intergroupe Francophone du Myélome and the Swiss Group for Clinical Cancer Research (2006) Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107:3474–3480. https://doi.org/10.1182/blood-2005-09-3869', 'volume': '107'}, 'key': '4514_CR2', 'year': 2006, 'container_name': 'Blood', 'title': None, 'locator': '3474'}
{'index': 2, 'target_release_id': None, 'extra': {'authors': ['B Bruno'], 'doi': '10.1056/nejmoa065464', 'unstructured': 'Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R, Omedè P, Baldi I, Bringhen S, Massaia M, Aglietta M, Levis A, Gallamini A, Fanin R, Palumbo A, Storb R, Ciccone G, Boccadoro M (2007) A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356:1110–1120. https://doi.org/10.1056/NEJMoa065464', 'volume': '356'}, 'key': '4514_CR3', 'year': 2007, 'container_name': 'N Engl J Med', 'title': None, 'locator': '1110'}
{'index': 3, 'target_release_id': None, 'extra': {'authors': ['G Gahrton'], 'doi': '10.1182/blood-2012-11-469452', 'unstructured': 'Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee (2013) Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long term results of the EBMT-NMAM2000 study. Blood 121:5055–5063. https://doi.org/10.1182/blood-2012-11-469452', 'volume': '121'}, 'key': '4514_CR4', 'year': 2013, 'container_name': 'Blood', 'title': None, 'locator': '5055'}
{'index': 4, 'target_release_id': None, 'extra': {'authors': ['C Gran'], 'doi': '10.1111/bjh.16642', 'unstructured': 'Gran C, Wang J, Nahi H, Koster L, Gahrton G, Einsele H, Niittyvoupio R, Edinger M, Beelen D, Ciceri F, Bornhäuser M, Finke J, Wreede LC, Ljungman P, Mielke S, Tischer J, Garderet L, Schönland S, Yakoub-Agha I, Kröger N (2020) Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT. Br J Haematol 189:e213–e217. https://doi.org/10.1111/bjh.16642', 'volume': '189'}, 'key': '4514_CR5', 'year': 2020, 'container_name': 'Br J Haematol', 'title': None, 'locator': 'e213'}
{'index': 5, 'target_release_id': None, 'extra': {'authors': ['C Greil'], 'doi': '10.3324/haematol.2018.200881', 'unstructured': 'Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wäsch R (2019) Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica 104:370–379. https://doi.org/10.3324/haematol.2018.200881', 'volume': '104'}, 'key': '4514_CR6', 'year': 2019, 'container_name': 'Haematologica', 'title': None, 'locator': '370'}
{'index': 6, 'target_release_id': None, 'extra': {'authors': ['B Björkstrand'], 'doi': '10.1200/jco.2010.32.7312', 'unstructured': 'Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G (2011) Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 29:3016–3022. https://doi.org/10.1200/JCO.2010.32.7312', 'volume': '29'}, 'key': '4514_CR7', 'year': 2011, 'container_name': 'J Clin Oncol', 'title': None, 'locator': '3016'}
{'index': 7, 'target_release_id': None, 'extra': {'authors': ['L Rosinol'], 'doi': '10.1182/blood-2008-02-141598', 'unstructured': 'Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al (2008) A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112:3591–3593. https://doi.org/10.1182/blood-2008-02-141598', 'volume': '112'}, 'key': '4514_CR8', 'year': 2008, 'container_name': 'Blood', 'title': None, 'locator': '3591'}
{'index': 8, 'target_release_id': None, 'extra': {'authors': ['A Krishnan'], 'doi': '10.1016/s1470-2045(11)70243-1', 'unstructured': 'Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E et al (2011) Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 12:1195–1203. https://doi.org/10.1016/S1470-2045(11)70243-1', 'volume': '12'}, 'key': '4514_CR9', 'year': 2011, 'container_name': 'Lancet Oncol', 'title': None, 'locator': '1195'}
{'index': 9, 'target_release_id': None, 'extra': {'authors': ['G Tricot'], 'doi': '10.1182/blood.v87.3.1196.bloodjournal8731196', 'unstructured': 'Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B (1996) Graft-versus-myeloma effect: proof of principle. Blood 87:1196–1198', 'volume': '87'}, 'key': '4514_CR10', 'year': 1996, 'container_name': 'Blood', 'title': None, 'locator': '1196'}
{'index': 10, 'target_release_id': None, 'extra': {'authors': ['S Knop'], 'doi': '10.1038/s41375-019-0537-2', 'unstructured': 'Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Deutsche Studiengruppe Multiples Myelom et al (2019) Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia 33:2710–2719. https://doi.org/10.1038/s41375-019-0537-2', 'volume': '33'}, 'key': '4514_CR11', 'year': 2019, 'container_name': 'Leukemia', 'title': None, 'locator': '2710'}
{'index': 11, 'target_release_id': None, 'extra': {'authors': ['D Roos-Weil'], 'doi': '10.3324/haematol.2011.042713', 'unstructured': 'Roos-Weil D, Moreau P, Avet-Loiseau H, Golmard JL, Kuentz M, Vigouroux S, Socie G, Furst S, Soulier J, le Gouill S, Francois S, Thiebaut A, Buzyn A, Maillard N, Yakoub-Agha I, Raus N, Fermand JP, Michallet M, Blaise D, Dhedin N, for the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC), Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) (2011) Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica 96:1504–1511. https://doi.org/10.3324/haematol.2011.042713', 'volume': '96'}, 'key': '4514_CR12', 'year': 2011, 'container_name': 'Haematologica', 'title': None, 'locator': '1504'}
{'index': 12, 'target_release_id': None, 'extra': {'authors': ['L Rasche'], 'doi': '10.1016/j.bbmt.2016.08.024', 'unstructured': 'Rasche L, Röllig C, Stuhler G, Danhof S, Mielke S, Grigoleit GU, Dissen L, Schemmel L, Middeke JM, Rücker V, Schreder M, Schetelig J, Bornhäuser M, Einsele H, Thiede C, Knop S (2016) Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features. Biol Blood Marrow Transplant 22:1988–1996. https://doi.org/10.1016/j.bbmt.2016.08.024', 'volume': '22'}, 'key': '4514_CR13', 'year': 2016, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '1988'}
{'index': 13, 'target_release_id': None, 'extra': {'authors': ['N Kröger'], 'doi': '10.1016/j.bbmt.2012.10.008', 'unstructured': 'Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander AR (2013) Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 19:398–404. https://doi.org/10.1016/j.bbmt.2012.10.008', 'volume': '19'}, 'key': '4514_CR14', 'year': 2013, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '398'}
{'index': 14, 'target_release_id': None, 'extra': {'authors': ['E Maffini'], 'doi': '10.3324/haematol.2018.200253', 'unstructured': 'Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R (2019) Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica 104:380–391. https://doi.org/10.3324/haematol.2018.200253', 'volume': '104'}, 'key': '4514_CR15', 'year': 2019, 'container_name': 'Haematologica', 'title': None, 'locator': '380'}
{'index': 15, 'target_release_id': None, 'extra': {'authors': ['H Maymani'], 'doi': '10.1016/j.bbmt.2019.01.009', 'unstructured': 'Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH (2019) Comparison of outcomes of allogeneic hematopoietic cell transplantation for multiple myeloma using three different conditioning regimens. Biol Blood Marrow Transplant 25:1039–1044. https://doi.org/10.1016/j.bbmt.2019.01.009', 'volume': '25'}, 'key': '4514_CR16', 'year': 2019, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '1039'}
{'index': 16, 'target_release_id': None, 'extra': {'authors': ['WI Gonsalves'], 'doi': '10.1038/s41409-018-0264-8', 'unstructured': 'Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V (2019) Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant 54:353–367. https://doi.org/10.1038/s41409-018-0264-8', 'volume': '54'}, 'key': '4514_CR17', 'year': 2019, 'container_name': 'Bone Marrow Transplant', 'title': None, 'locator': '353'}
{'index': 17, 'target_release_id': None, 'extra': {'authors': ['P Moreau'], 'doi': '10.1093/annonc/mdx096', 'unstructured': 'Moreau P, San Miguel JF, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H et al (2017) ESMO Guidelines Committee. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv52–iv61. https://doi.org/10.1093/annonc/mdx096', 'volume': '28'}, 'key': '4514_CR18', 'year': 2017, 'container_name': 'Ann Oncol', 'title': None, 'locator': 'iv52'}
{'index': 18, 'target_release_id': None, 'extra': {'authors': ['F Gay'], 'doi': '10.3324/haematol.2017.174573', 'unstructured': 'Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P (2018) From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica 103:197–211. https://doi.org/10.3324/haematol.2017.174573', 'volume': '103'}, 'key': '4514_CR19', 'year': 2018, 'container_name': 'Haematologica', 'title': None, 'locator': '197'}
{'index': 19, 'target_release_id': None, 'extra': {'authors': ['M Sobh'], 'doi': '10.1038/leu.2016.101', 'unstructured': 'Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, el-Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N (2016) Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia 30:2047–2054. https://doi.org/10.1038/leu.2016.101', 'volume': '30'}, 'key': '4514_CR20', 'year': 2016, 'container_name': 'Leukemia', 'title': None, 'locator': '2047'}
{'index': 20, 'target_release_id': None, 'extra': {'authors': ['A Palumbo'], 'doi': '10.1200/jco.2015.61.2267', 'unstructured': 'Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol 33:2863–2869. https://doi.org/10.1200/JCO.2015.61.2267', 'volume': '33'}, 'key': '4514_CR21', 'year': 2015, 'container_name': 'J Clin Oncol', 'title': None, 'locator': '2863'}
{'index': 21, 'target_release_id': None, 'extra': {'authors': ['A Bacigalupo'], 'doi': '10.1016/j.bbmt.2009.07.004', 'unstructured': 'Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15:1628–1633. https://doi.org/10.1016/j.bbmt.2009.07.004', 'volume': '15'}, 'key': '4514_CR22', 'year': 2009, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '1628'}
{'index': 22, 'target_release_id': None, 'extra': {'authors': ['A Shimoni'], 'doi': '10.1016/j.bbmt.2017.12.776', 'unstructured': 'Shimoni A, Labopin M, Savani B, Hamladji RM, Beelen D, Mufti G, Socié G, Delage J, Blaise D, Chevallier P, Forcade E, Deconinck E, Mohty M, Nagler A (2018) Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 24:751–757. https://doi.org/10.1016/j.bbmt.2017.12.776', 'volume': '24'}, 'key': '4514_CR23', 'year': 2018, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '751'}
{'index': 23, 'target_release_id': None, 'extra': {'authors': ['D Przepiorka'], 'unstructured': 'Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on AGvHD grading. Bone Marrow Transplant 15:825–828', 'volume': '15'}, 'key': '4514_CR24', 'year': 1995, 'container_name': 'Bone Marrow Transplant', 'title': None, 'locator': '825'}
{'index': 24, 'target_release_id': None, 'extra': {'authors': ['MH Jagasia'], 'doi': '10.1016/j.bbmt.2014.12.001', 'unstructured': 'Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21:389–401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001', 'volume': '21'}, 'key': '4514_CR25', 'year': 2015, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '389–401.e1'}
{'index': 25, 'target_release_id': None, 'extra': {'authors': ['S Kumar'], 'doi': '10.1016/s1470-2045(16)30206-6', 'unstructured': 'Kumar S (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6', 'volume': '17'}, 'key': '4514_CR26', 'year': 2016, 'container_name': 'Lancet Oncol', 'title': None, 'locator': 'e328'}
{'index': 26, 'target_release_id': None, 'extra': {'authors': ['SG Holtan'], 'doi': '10.1182/blood-2014-10-609032', 'unstructured': 'Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG et al (2015) Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125:1333–1338. https://doi.org/10.1182/blood-2014-10-609032', 'volume': '125'}, 'key': '4514_CR27', 'year': 2015, 'container_name': 'Blood', 'title': None, 'locator': '1333'}
{'index': 27, 'target_release_id': None, 'extra': {'authors': ['S Iacobelli'], 'doi': '10.1038/bmt.2012.282', 'unstructured': 'Iacobelli S (2013) Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 48:S1–S37. https://doi.org/10.1038/bmt.2012.282', 'volume': '48'}, 'key': '4514_CR28', 'year': 2013, 'container_name': 'Bone Marrow Transplant', 'title': None, 'locator': 'S1'}
{'index': 28, 'target_release_id': None, 'extra': {'unstructured': 'R Foundation for Statistical Computing, Vienna, Austria. R: a language and environment for statistical computing. URL https://www.R-project.org/.'}, 'key': '4514_CR29', 'year': None, 'container_name': None, 'title': None, 'locator': None}
{'index': 29, 'target_release_id': None, 'extra': {'authors': ['J Casper'], 'doi': '10.1200/jco.2009.23.3429', 'unstructured': 'Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kröger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeier U, Freund M (2010) Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 28:3344–3351. https://doi.org/10.1200/JCO.2009.23.3429', 'volume': '28'}, 'key': '4514_CR30', 'year': 2010, 'container_name': 'J Clin Oncol', 'title': None, 'locator': '3344'}
{'index': 30, 'target_release_id': None, 'extra': {'authors': ['L Giaccone'], 'doi': '10.1016/j.bbmt.2017.09.017', 'unstructured': 'Giaccone L, Evangelista A, Patriarca F, Sorasio R, Pini M, Carnevale-Schianca F, Festuccia M, Brunello L, Zallio F, Maffini E, Omedé P, Bringhen S, Mordini N, Fanin R, Ciccone G, Boccadoro M, Bruno B (2018) Impact of new drugs on the long-term follow-up of upfront tandem autograft-allograft in multiple myeloma. Biol Blood Marrow Transplant 24:189–193. https://doi.org/10.1016/j.bbmt.2017.09.017', 'volume': '24'}, 'key': '4514_CR31', 'year': 2018, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '189'}
{'index': 31, 'target_release_id': None, 'extra': {'authors': ['R Passera'], 'doi': '10.1016/j.bbmt.2013.03.012', 'unstructured': 'Passera R, Pollichieni S, Brunello L, Patriarca F, Bonifazi F, Montefusco V, Falda M, Montanari M, Guidi S, Giaccone L, Mordini N, Carella AM, Bavaro P, Milone G, Benedetti F, Ciceri F, Scimè R, Benedetti E, Castagna L, Festuccia M, Rambaldi A, Bacigalupo A, Corradini P, Bosi A, Boccadoro M, Bandini G, Fanin R, Bruno B (2013) Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. Biol Blood Marrow Transplant 19:940–948. https://doi.org/10.1016/j.bbmt.2013.03.012', 'volume': '19'}, 'key': '4514_CR32', 'year': 2013, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '940'}
{'index': 32, 'target_release_id': None, 'extra': {'authors': ['LE Franssen'], 'doi': '10.1111/ejh.12758', 'unstructured': 'Franssen LE, Raymakers RA, Buijs A, Schmitz MF, van Dorp S, Mutis T et al (2016) Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution. Eur J Haematol 97:479–488. https://doi.org/10.1111/ejh.12758', 'volume': '97'}, 'key': '4514_CR33', 'year': 2016, 'container_name': 'Eur J Haematol', 'title': None, 'locator': '479'}
{'index': 33, 'target_release_id': None, 'extra': {'authors': ['LJ Costa'], 'doi': '10.1038/s41409-020-0887-4', 'unstructured': 'Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J, Schonland S, Evangelista A, Perez-Simon JA, Hari P, Brown EE, Giralt SA, Patriarca F, Stadtmauer EA, Rosinol L, Krishnan AY, Gahrton G, Bruno B (2020) Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transplant. 55:1810–1816. https://doi.org/10.1038/s41409-020-0887-4', 'volume': '55'}, 'key': '4514_CR34', 'year': 2020, 'container_name': 'Bone Marrow Transplant.', 'title': None, 'locator': '1810'}
{'index': 34, 'target_release_id': None, 'extra': {'authors': ['S Chhabra'], 'doi': '10.1016/j.bbmt.2020.02.020', 'unstructured': "Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN (2020) Relapse after allogeneic hematopoietic cell transplantation for multiple myeloma: survival outcomes and factors influencing them. Biol Blood Marrow Transplant. 26:1288–1297. https://doi.org/10.1016/j.bbmt.2020.02.020", 'volume': '26'}, 'key': '4514_CR35', 'year': 2020, 'container_name': 'Biol Blood Marrow Transplant.', 'title': None, 'locator': '1288'}
{'index': 35, 'target_release_id': None, 'extra': {'authors': ['L López-Corral'], 'doi': '10.1016/j.bbmt.2019.04.026', 'unstructured': 'López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA (2019) Response to novel drugs before and after allogeneic stem cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transplant 25:1703–1712. https://doi.org/10.1016/j.bbmt.2019.04.026', 'volume': '25'}, 'key': '4514_CR36', 'year': 2019, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '1703'}
{'index': 36, 'target_release_id': None, 'extra': {'authors': ['JA Pérez-Simón'], 'doi': '10.1046/j.1365-2141.2003.04237.x', 'unstructured': 'Pérez-Simón JA, Martino R, Alegre A, Tomás JF, De Leon A, Caballero D et al (2003) Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 121:104–108. https://doi.org/10.1046/j.1365-2141.2003.04237.x', 'volume': '121'}, 'key': '4514_CR37', 'year': 2003, 'container_name': 'Br J Haematol', 'title': None, 'locator': '104'}
{'index': 37, 'target_release_id': None, 'extra': {'authors': ['S Gerull'], 'doi': '10.1038/sj.bmt.1705161', 'unstructured': 'Gerull S, Goerner M, Benner A, Hegenbart U, Klein U, Schaefer H, Goldschmidt H, Ho AD (2005) Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 36:963–969. https://doi.org/10.1038/sj.bmt.1705161', 'volume': '36'}, 'key': '4514_CR38', 'year': 2005, 'container_name': 'Bone Marrow Transplant', 'title': None, 'locator': '963'}
{'index': 38, 'target_release_id': None, 'extra': {'authors': ['F Patriarca'], 'doi': '10.1016/j.bbmt.2011.07.026', 'unstructured': 'Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C, Nozza A, Sperotto A, Morabito F, Stuhler G, Festuccia M, Bosi A, Fanin R, Corradini P (2012) Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant 18:617–626. https://doi.org/10.1016/j.bbmt.2011.07.026', 'volume': '18'}, 'key': '4514_CR39', 'year': 2012, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '617'}
{'index': 39, 'target_release_id': None, 'extra': {'authors': ['M Htut'], 'doi': '10.1016/j.bbmt.2017.10.024', 'unstructured': "Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P (2018) Autologous/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival. Biol Blood Marrow Transplant 24:478–485. https://doi.org/10.1016/j.bbmt.2017.10.024", 'volume': '24'}, 'key': '4514_CR40', 'year': 2018, 'container_name': 'Biol Blood Marrow Transplant', 'title': None, 'locator': '478'}
{'index': 40, 'target_release_id': None, 'extra': {'authors': ['PJ Hayden'], 'doi': '10.1111/ejh.13352', 'unstructured': 'Hayden PJ, Iacobelli S, Pérez-Simón JA, van Biezen A, Minnema M, Niittyvuopio R et al (2020) Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. Eur J Haematol 104:181–189. https://doi.org/10.1111/ejh.13352', 'volume': '104'}, 'key': '4514_CR41', 'year': 2020, 'container_name': 'Eur J Haematol', 'title': None, 'locator': '181'}
{'index': 41, 'target_release_id': None, 'extra': {'authors': ['M Schmidt-Hieber'], 'doi': '10.1038/sj.bmt.1705605', 'unstructured': 'Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H, Kanz L, Keilholz U, Marinets O, Beelen DW, Fauser AA, Volin L, Ruutu T, Uharek L, Fietz T, Knauf W, Hopfenmüller W, Thiel E, Freund M, Casper J (2007) Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 39:389–396. https://doi.org/10.1038/sj.bmt.1705605', 'volume': '39'}, 'key': '4514_CR42', 'year': 2007, 'container_name': 'Bone Marrow Transplant', 'title': None, 'locator': '389'}
{'index': 42, 'target_release_id': None, 'extra': {'authors': ['A Urbano-Ispizua'], 'doi': '10.1038/sj.bmt.1703535', 'unstructured': 'Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H et al (2002) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 29:639–646. https://doi.org/10.1038/sj.bmt.1703535', 'volume': '29'}, 'key': '4514_CR43', 'year': 2002, 'container_name': 'Bone Marrow Transplant.', 'title': None, 'locator': '639'}
{'index': 43, 'target_release_id': None, 'extra': {'authors': ['V Jindal'], 'doi': '10.1097/coc.0000000000000669', 'unstructured': 'Jindal V, Khoury J, Gupta R, Jaiyesimi I (2020) Current status of chimeric antigen receptor T-cell therapy in multiple myeloma. Am J Clin Oncol. 43:371–377. https://doi.org/10.1097/COC.0000000000000669', 'volume': '43'}, 'key': '4514_CR44', 'year': 2020, 'container_name': 'Am J Clin Oncol.', 'title': None, 'locator': '371'}
{'index': 44, 'target_release_id': None, 'extra': {'authors': ['UA Shah'], 'doi': '10.1016/j.beha.2020.101141', 'unstructured': 'Shah UA, Mailankody S (2020) CAR T and CAR NK cells in multiple myeloma: expanding the targets. Best Pract Res Clin Haematol. 33:101141. https://doi.org/10.1016/j.beha.2020.101141', 'volume': '33'}, 'key': '4514_CR45', 'year': 2020, 'container_name': 'Best Pract Res Clin Haematol.', 'title': None, 'locator': '101141'}
{'index': 45, 'target_release_id': None, 'extra': {'authors': ['H Einsele'], 'doi': '10.1038/s41409-019-0596-z', 'issue': 'Suppl 2', 'unstructured': 'Einsele H, Rasche L, Topp MS, Martin Kortüm K, Duell J (2019) The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT. Bone Marrow Transplant. 54(Suppl 2):721–726. https://doi.org/10.1038/s41409-019-0596-z', 'volume': '54'}, 'key': '4514_CR46', 'year': 2019, 'container_name': 'Bone Marrow Transplant.', 'title': None, 'locator': '721'}
{'index': 46, 'target_release_id': None, 'extra': {'authors': ['T Caballero-Velázquez'], 'doi': '10.1038/s41409-019-0670-6', 'unstructured': 'Caballero-Velázquez T, Calderón-Cabrera C, López-Corral L, Puig N, Marquez-Malaver F, Pérez-López E, European Myeloma Network et al (2020) Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. Bone Marrow Transplant. 55:419–430. https://doi.org/10.1038/s41409-019-0670-6', 'volume': '55'}, 'key': '4514_CR47', 'year': 2020, 'container_name': 'Bone Marrow Transplant.', 'title': None, 'locator': '419'}
{'index': 47, 'target_release_id': None, 'extra': {'authors': ['C Wolschke'], 'doi': '10.1016/j.exphem.2012.10.004', 'unstructured': 'Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y et al (2013) Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I/II dose-finding study. Exp Hematol 41:134-142.e3. https://doi.org/10.1016/j.exphem.2012.10.004', 'volume': '41'}, 'key': '4514_CR48', 'year': 2013, 'container_name': 'Exp Hematol', 'title': None, 'locator': '134-142.e3'}
{'index': 48, 'target_release_id': None, 'extra': {'authors': ['N Kröger'], 'doi': '10.1016/j.exphem.2006.02.020', 'unstructured': 'Kröger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A (2006) Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol. 34:770–775. https://doi.org/10.1016/j.exphem.2006.02.020', 'volume': '34'}, 'key': '4514_CR49', 'year': 2006, 'container_name': 'Exp Hematol.', 'title': None, 'locator': '770'}
{'index': 49, 'target_release_id': None, 'extra': {'authors': ['N Kröger'], 'doi': '10.1038/bmt.2012.142', 'unstructured': 'Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger KH, Burchert A, Stübig T, Wolschke C, Ayuk F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander AR (2013) Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant. 48:403–407. https://doi.org/10.1038/bmt.2012.142', 'volume': '48'}, 'key': '4514_CR50', 'year': 2013, 'container_name': 'Bone Marrow Transplant.', 'title': None, 'locator': '403'}
|